(R)-7-methyl-3-(propylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrothieno[3,4-c]pyridin-4(5H)-one

ID: ALA3797869

Chembl Id: CHEMBL3797869

PubChem CID: 89889447

Max Phase: Preclinical

Molecular Formula: C14H17N3OS2

Molecular Weight: 307.44

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCSc1sc(-c2cc[nH]n2)c2c1C(=O)NC[C@@H]2C

Standard InChI:  InChI=1S/C14H17N3OS2/c1-3-6-19-14-11-10(8(2)7-15-13(11)18)12(20-14)9-4-5-16-17-9/h4-5,8H,3,6-7H2,1-2H3,(H,15,18)(H,16,17)/t8-/m0/s1

Standard InChI Key:  BNWXGAMIAABLQP-QMMMGPOBSA-N

Associated Targets(Human)

LRRK2 Tchem Leucine-rich repeat serine/threonine-protein kinase 2 (6390 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cerebrospinal fluid (288 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 307.44Molecular Weight (Monoisotopic): 307.0813AlogP: 3.49#Rotatable Bonds: 4
Polar Surface Area: 57.78Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 13.86CX Basic pKa: 1.86CX LogP: 3.14CX LogD: 3.14
Aromatic Rings: 2Heavy Atoms: 20QED Weighted: 0.85Np Likeness Score: -0.60

References

1. Greshock TJ, Sanders JM, Drolet RE, Rajapakse HA, Chang RK, Kim B, Rada VL, Tiscia HE, Su H, Lai MT, Sur SM, Sanchez RI, Bilodeau MT, Renger JJ, Kern JT, McCauley JA..  (2016)  Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.,  26  (11): [PMID:27106707] [10.1016/j.bmcl.2016.04.021]

Source